Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.40 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193204 | 0.91 | TSHR (0.47) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL21869041 | 0.87 | TSHR (0.38) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL18949239 | 0.85 | TSHR (0.46) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL2531577 | 0.85 | TSHR (0.56) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL12018013 | 0.84 | SCN1A (0.48) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL15713250 | 0.83 | TSHR (0.53) | TSHRALDH1A1SCN1ASCN2ASCN3A | |
| SCHEMBL19316647 | 0.81 | TSHR (0.39) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL19316649 | 0.81 | TSHR (0.39) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL22667518 | 0.81 | TSHR (0.49) | TSHRALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL28606185 | 0.80 | TSHR (0.48) | TSHRALDH1A1ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | TOKUYAMA DENTAL CORPORATION (JP) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253555-A1 | POLYMERIZABLE MONOMER, METHOD OF PRODUCING POLYMERIZABLE MONOMER, CURABLE COMPOSITION AND RESIN MEMBER | H1-0, VMP1, CHRM1 | TSHR 3456/4885ALDH1A1 1350/4885ADRB2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.